Candel Therapeutics (CADL) Return on Sales (2020 - 2022)

Candel Therapeutics has disclosed Return on Sales across 3 years of filings, most recently posting 2.54% for Q4 2022.

• Return on Sales for Q4 2022 came in at 2.54%, up 1038.0% year-over-year; the trailing twelve-month figure through Dec 2022 was 2.84% (down 24.0% YoY), and the FY2022 annual result was 2.82%, down 24.0% from the prior year.
• Return on Sales came in at 2.54% for Q4 2022 at Candel Therapeutics, up from 2.92% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.81% in Q2 2020 to a low of 12.92% in Q4 2021.
• The 3-year median for Return on Sales is 2.54% (2022), against an average of 3.07%.
• Across the five-year window, Return on Sales slumped 1096 bps in 2021 and surged 1038 bps in 2022, its largest moves.
• Candel Therapeutics' Return on Sales stood at 1.96% in 2020, then slumped by 559 bps to 12.92% in 2021, then jumped by 80 bps to 2.54% in 2022.
• The last three Return on Sales figures came in at 2.54% (Q4 2022), 2.92% (Q3 2022), and 2.94% (Q2 2022), per Business Quant data.